[go: up one dir, main page]

DK3311828T3 - Modificerede vasoaktive tarmpeptider - Google Patents

Modificerede vasoaktive tarmpeptider Download PDF

Info

Publication number
DK3311828T3
DK3311828T3 DK17163446.2T DK17163446T DK3311828T3 DK 3311828 T3 DK3311828 T3 DK 3311828T3 DK 17163446 T DK17163446 T DK 17163446T DK 3311828 T3 DK3311828 T3 DK 3311828T3
Authority
DK
Denmark
Prior art keywords
piptides
vasoactive intestinal
modified vasoactive
modified
intestinal
Prior art date
Application number
DK17163446.2T
Other languages
English (en)
Inventor
Homayoun Sadeghi
Andrew Turner
Suzanne Dagher
Original Assignee
Phasebio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phasebio Pharmaceuticals Inc filed Critical Phasebio Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3311828T3 publication Critical patent/DK3311828T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2278Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK17163446.2T 2009-08-14 2010-08-16 Modificerede vasoaktive tarmpeptider DK3311828T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23415109P 2009-08-14 2009-08-14
EP10808864.2A EP2464370B1 (en) 2009-08-14 2010-08-16 Modified vasoactive intestinal peptides

Publications (1)

Publication Number Publication Date
DK3311828T3 true DK3311828T3 (da) 2021-06-28

Family

ID=43586545

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10808864.2T DK2464370T3 (da) 2009-08-14 2010-08-16 Modificerede vasoaktive intestinale peptider
DK17163446.2T DK3311828T3 (da) 2009-08-14 2010-08-16 Modificerede vasoaktive tarmpeptider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10808864.2T DK2464370T3 (da) 2009-08-14 2010-08-16 Modificerede vasoaktive intestinale peptider

Country Status (19)

Country Link
US (5) US9029505B2 (da)
EP (2) EP2464370B1 (da)
JP (3) JP5801807B2 (da)
KR (2) KR101943420B1 (da)
CN (1) CN102596217B (da)
AU (3) AU2010282250B2 (da)
BR (1) BR112012003327A2 (da)
CA (1) CA2804755C (da)
DK (2) DK2464370T3 (da)
ES (2) ES2870914T3 (da)
HU (2) HUE032703T2 (da)
IL (1) IL218116A (da)
IN (1) IN2012DN02120A (da)
MX (2) MX339031B (da)
PL (2) PL2464370T3 (da)
PT (2) PT2464370T (da)
RU (1) RU2589255C2 (da)
SG (1) SG10201407329RA (da)
WO (1) WO2011020091A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
RU2589255C2 (ru) 2009-08-14 2016-07-10 Фейзбайо Фармасьютикалз, Инк. Модифицированные вазоактивные интестинальные пептиды
US9561262B2 (en) * 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2013028989A1 (en) * 2011-08-24 2013-02-28 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
HK1202067A1 (en) * 2011-11-28 2015-09-18 Phasebio Pharmaceuticals, Inc. Therapeutic agents comprising insulin amino acid sequences
WO2014081849A1 (en) * 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
AU2015255752B2 (en) * 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
EP3220936A4 (en) 2014-11-21 2018-08-22 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
CN105753990B (zh) * 2014-12-19 2018-07-03 兰州大学 一种血管活性肠肽的融合蛋白及其制备方法和应用
EP3256151B1 (en) 2015-02-09 2020-08-05 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2017152399A1 (zh) * 2016-03-09 2017-09-14 兰州大学 一种血管活性肠肽的融合蛋白及其制备方法和应用
MX2018013546A (es) 2016-05-06 2019-04-22 Phasebio Pharmaceuticals Inc Proteinas de fusion de elp para liberacion controlada y sostenida.
CN107056922A (zh) * 2016-12-24 2017-08-18 山东明鑫集团有限公司 一种具有降血糖作用的pacap多肽类似物的制备方法
WO2019240881A2 (en) * 2018-04-23 2019-12-19 Emory University Vip and vip agonists, nanoparticles, and uses in inflammatory t-cell mediated disease
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
KR102719035B1 (ko) * 2020-04-20 2024-10-18 주식회사 리비옴 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도
US20230173030A1 (en) * 2020-05-05 2023-06-08 Phasebio Pharmaceuticals, Inc. Vasoactive intestinal peptide fusion proteins for the treatment of covid-19
WO2022224172A1 (en) 2021-04-20 2022-10-27 Advita Lifescience Ag Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome
DE102024001175A1 (de) 2024-04-04 2025-10-09 ReViSan Healthcare GmbH Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege.
CN119390812B (zh) * 2024-11-08 2025-07-29 三亚市私域大健康医院有限公司 一种治疗勃起功能障碍的干细胞外泌体组合物及其用途

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187852A (en) * 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
US4132746A (en) * 1976-07-09 1979-01-02 University Of Alabama, Birmingham Medical & Education Foundation Synthetic elastomeric insoluble cross-linked polypentapeptide
US4474851A (en) 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4500700A (en) 1981-10-02 1985-02-19 The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three
US4589882A (en) * 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4749647A (en) * 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
US4605641A (en) * 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4734400A (en) 1984-10-09 1988-03-29 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4783523A (en) * 1986-08-27 1988-11-08 Urry Dan W Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides
US4870055A (en) * 1986-04-17 1989-09-26 University Of Alabama At Birmingham Segmented polypeptide bioelastomers to modulate elastic modulus
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US4898926A (en) * 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
US5496712A (en) * 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US5830713A (en) * 1986-11-04 1998-11-03 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5773249A (en) * 1986-11-04 1998-06-30 Protein Polymer Technologies, Inc. High molecular weight collagen-like protein polymers
US5770697A (en) * 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5243038A (en) * 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US5641648A (en) * 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US6184348B1 (en) * 1986-11-04 2001-02-06 Protein Polymer Technologies Functional recombinantly prepared synthetic protein polymer
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4939224A (en) 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5234907A (en) * 1989-06-30 1993-08-10 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US5141924A (en) 1989-06-30 1992-08-25 Hoffmann-La Roche, Inc. Synthetic vasoactive intestinal peptide analogs
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
DE69105323T2 (de) 1990-03-27 1995-06-01 Bioelastics Res Ltd Bioelastomeres Arzneimittelabgabesystem.
ES2063406T3 (es) * 1990-06-26 1995-01-01 Sanwa Kagaku Kenkyusho Co Procedimiento para la preparacion de analogos de polipeptido intestinal vasoactivo.
JPH07108232B2 (ja) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US5235041A (en) * 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5393602A (en) * 1991-04-19 1995-02-28 Bioelastics Research Ltd. Superabsorbent materials and uses thereof
JPH05238950A (ja) * 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性vip製剤
US5958881A (en) * 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
AU656230B2 (en) 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
US5681816A (en) * 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5900405A (en) * 1994-01-24 1999-05-04 Bioelastics Research, Ltd. Polymers responsive to electrical energy
CA2187322A1 (en) * 1994-04-07 1995-10-19 Israel Rubinstein Vasoactive intestinal polypeptide
US5527610A (en) * 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US6004782A (en) 1995-04-14 1999-12-21 Bioelastics Research Ltd. Hyperexpression of bioelastic polypeptides
US5972406A (en) * 1995-04-14 1999-10-26 Bioelastics Research Ltd. Bioelastomers suitable as food product additives
US5854387A (en) 1995-04-14 1998-12-29 Bioelastics Research, Ltd. Simple method for the purification of a bioelastic polymer
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6037321A (en) * 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
AU716154B2 (en) 1995-09-01 2000-02-17 University Of Washington Interactive molecular conjugates
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
CN1186355C (zh) 1996-02-09 2005-01-26 霍夫曼-拉罗奇有限公司 血管活性肠肽类似物的合成
CN1300173C (zh) * 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5816259A (en) * 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043271A1 (en) * 1998-02-27 1999-09-02 Bioelastics Research, Ltd. Injectable implants for tissue augmentation and restoration
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US20020151458A1 (en) * 1998-04-17 2002-10-17 Perez Gomariz Rosa Maria Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists
ES2138561B1 (es) * 1998-04-17 2000-07-01 Univ Madrid Complutense Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6541033B1 (en) * 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU3867400A (en) * 1999-03-19 2000-10-09 Duke University Methods of using bioelastomers
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
JP2004500906A (ja) * 1999-11-12 2004-01-15 ルーベン, レオ 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド
US6235264B1 (en) * 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US6593394B1 (en) * 2000-01-03 2003-07-15 Prosperous Kingdom Limited Bioactive and osteoporotic bone cement
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
DE60033697D1 (de) 2000-02-18 2007-04-12 Dabur Res Foundation Sahibabad Radiomarkierte vip-analoge zur diagnose und therapie
WO2001060862A1 (en) 2000-02-18 2001-08-23 Dabur Research Foundation Vasoactive intestinal peptide analogs
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US6852834B2 (en) * 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
ATE346093T1 (de) * 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
AU2001273632A1 (en) 2000-06-23 2002-01-08 Drexel University Polymeric, fiber matrix delivery systems for bioactive compounds
CN1487952A (zh) * 2000-11-28 2004-04-07 �ɶ����\��ʵ���� 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
JP2004528014A (ja) * 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Glp−1融合タンパク質
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
BR0212080A (pt) * 2001-08-23 2006-04-04 Lilly Co Eli composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
KR20040065212A (ko) 2001-11-06 2004-07-21 센주 세이야꾸 가부시키가이샤 건조안 및 건조안과 연관된 질환의 치료제
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
CA2488358A1 (en) 2002-06-10 2003-12-18 Mondobiotech Laboratories Anstalt Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
AU2003284428B2 (en) * 2002-11-27 2010-08-26 Ils Inc. Peptides and medicinal compositions containing the same
US20040234609A1 (en) * 2003-05-14 2004-11-25 Collier Katherine D. Repeat sequence protein polymer active agent congjugates, methods and uses
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
WO2005004899A2 (de) 2003-07-14 2005-01-20 Mondobiotech Laboratories Anstalt Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen
WO2005014030A1 (en) * 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
US7776815B2 (en) * 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
US7928059B2 (en) 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
US20050203009A1 (en) * 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
JP2007530697A (ja) * 2004-03-29 2007-11-01 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ 両親媒性グリコペプチド
DE602005005476T2 (de) * 2004-05-21 2009-03-05 Eli Lilly And Co., Indianapolis Selektive peptidische agonisten des vpac2-rezeptors
WO2005120545A1 (en) * 2004-06-11 2005-12-22 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
EP1768686A4 (en) * 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
WO2006023356A2 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
AU2005294125A1 (en) * 2004-10-08 2006-04-20 Transition Therapeutics Inc. Vasoactive intestinal polypeptide pharmaceuticals
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
EP2664340B1 (en) 2005-06-24 2020-02-12 Duke University A direct drug delivery system based on thermally responsive biopolymers
EP1942941A1 (en) * 2005-10-26 2008-07-16 Eli Lilly And Company Selective vpac2 receptor peptide agonists
AU2006314037B2 (en) * 2005-11-18 2010-09-23 Dabur Pharma Limited Targeted fusion proteins for cancer therapy
EP2783697B1 (en) * 2005-12-09 2017-01-11 Vectus Biosystems Limited VIP Fragments and uses thereof
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8334257B2 (en) * 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8367626B2 (en) * 2006-05-12 2013-02-05 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
CN101578373A (zh) * 2006-09-06 2009-11-11 费斯生物制药公司 融合肽治疗组合物
EP2152741B1 (en) 2007-05-21 2011-09-21 Res International Sarl Peptides with improved properties having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
EP4074327A1 (en) * 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
RU2589255C2 (ru) * 2009-08-14 2016-07-10 Фейзбайо Фармасьютикалз, Инк. Модифицированные вазоактивные интестинальные пептиды
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US9605186B2 (en) 2012-09-19 2017-03-28 Exxonmobil Chemical Patents Inc. Adhesive compositions of ethylene-based and propylene-based polymers
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis

Also Published As

Publication number Publication date
JP2016000751A (ja) 2016-01-07
JP2013501818A (ja) 2013-01-17
EP3311828A1 (en) 2018-04-25
BR112012003327A2 (pt) 2017-06-06
US9029505B2 (en) 2015-05-12
MX2012001979A (es) 2012-06-25
KR101887009B1 (ko) 2018-08-09
PL2464370T3 (pl) 2017-08-31
US20110178017A1 (en) 2011-07-21
US9700598B2 (en) 2017-07-11
RU2589255C2 (ru) 2016-07-10
IL218116A0 (en) 2012-04-30
MX339031B (es) 2016-05-05
AU2017279636A1 (en) 2018-01-18
PT3311828T (pt) 2021-05-05
AU2016200897B2 (en) 2017-10-12
AU2010282250B2 (en) 2015-11-12
EP2464370A1 (en) 2012-06-20
US20160220642A1 (en) 2016-08-04
JP6069441B2 (ja) 2017-02-01
CN102596217B (zh) 2014-07-02
EP2464370A4 (en) 2013-03-27
PL3311828T3 (pl) 2021-11-22
JP6229038B2 (ja) 2017-11-08
RU2012109553A (ru) 2013-09-20
KR20120062777A (ko) 2012-06-14
WO2011020091A1 (en) 2011-02-17
KR20170085611A (ko) 2017-07-24
IL218116A (en) 2017-06-29
JP5801807B2 (ja) 2015-10-28
IN2012DN02120A (da) 2015-08-21
AU2016200897A1 (en) 2016-03-03
PT2464370T (pt) 2017-05-17
DK2464370T3 (da) 2017-05-15
JP2017066157A (ja) 2017-04-06
CA2804755C (en) 2018-06-05
EP3311828B1 (en) 2021-04-07
HUE032703T2 (en) 2017-10-30
AU2010282250A1 (en) 2012-04-05
ES2870914T3 (es) 2021-10-28
CN102596217A (zh) 2012-07-18
CA2804755A1 (en) 2011-02-17
SG10201407329RA (en) 2015-01-29
ES2624478T3 (es) 2017-07-14
HUE054744T2 (hu) 2021-12-28
KR101943420B1 (ko) 2019-04-17
US20240091313A1 (en) 2024-03-21
US20180008677A1 (en) 2018-01-11
MX366935B (es) 2019-07-31
AU2017279636B2 (en) 2019-09-12
US20250325635A1 (en) 2025-10-23
EP2464370B1 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
FIC20220037I1 (fi) Tebentafuspi
FIC20220003I1 (fi) Vosoritidi
DK3311828T3 (da) Modificerede vasoaktive tarmpeptider
NL300873I2 (nl) Venetoclax
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
EP2445547A4 (en) CATHETERISM SYSTEM
EP2440486A4 (en) CABLE RETRACTION SYSTEM
DK2430035T3 (da) Uracylspipooxetannukleosider
FI20095302A0 (fi) Luminesenssimääritysmenetelmä
DE112010002728A5 (de) Turboinhalator
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
FI20105601A0 (fi) Särmäyspuristin
DE202009005065U8 (de) Kartonverschließmaschine
DE102009034429A8 (de) Flachantenne
NO20090478L (no) Skifesteband
FI9141U1 (fi) Apuväline
DE112010004370A5 (de) Solarkollektorsystern
FR2942957B1 (fr) Pilulier
FI8702U1 (fi) Apuväline
IT1394218B1 (it) Set da ferrata
FI8687U1 (fi) Multauslaitteisto
FI8771U1 (fi) Desifiointilaite
FI8446U1 (fi) Pilkekone
FI8438U1 (fi) Osastoija
FI8626U1 (fi) Suojaelementtikiinnike